SCHEDULE: FMR LLC Discloses 13.6% Stake in Beam Therapeutics
Schedule 13G Amendment
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 13.6% beneficial ownership stake in Beam Therapeutics Inc. as of September 30, 2025.
Summary
- FMR LLC and Abigail P. Johnson jointly filed an Amendment No. 10 to Schedule 13G concerning their beneficial ownership in Beam Therapeutics Inc.
- They collectively beneficially own 13,766,517.70 shares of Beam Therapeutics Inc. common stock.
- This aggregate amount represents 13.6% of the total outstanding common stock.
- FMR LLC holds sole voting power over 13,755,225.00 shares and sole dispositive power over 13,766,517.70 shares.
- Abigail P. Johnson holds sole dispositive power over 13,766,517.70 shares, but no sole voting power.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of Beam Therapeutics Inc., nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by a major institutional investor, FMR LLC, and its CEO, Abigail P. Johnson, maintaining a substantial 13.6% stake in Beam Therapeutics Inc. This indicates continued confidence from a significant shareholder, which is a moderately positive signal.
Positives
- A significant institutional investor, FMR LLC, maintains a substantial 13.6% stake in Beam Therapeutics Inc., indicating continued confidence in the company.
Future Outlook
NA
Management Comments
- The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nominations under §§ 240.14a-11.
Industry Context
NA
Stakeholder Impact
- Shareholders: The disclosure of a significant, stable institutional ownership stake by FMR LLC may provide a degree of confidence to other shareholders regarding the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of FMR LLC. |
| 2023-01-10 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (Exhibit 24) was incorporated by reference. |
| 2023-01-26 | Effective date of Power of Attorney for Stephanie J. Brown on behalf of Abigail P. Johnson. |
| 2023-01-31 | Date of Schedule 13G filing by FMR LLC where Power of Attorney (Exhibit 24) for Abigail P. Johnson was incorporated by reference. |
| 2025-09-30 | Date of event which requires filing of this statement, reflecting beneficial ownership as of this date. |
| 2025-11-04 | Date of the joint filing agreement and signature date for this Schedule 13G. |
Recommendation
holdThe filing is a routine disclosure of a substantial, passive ownership stake by FMR LLC and Abigail P. Johnson in Beam Therapeutics Inc. The certification explicitly states the holding is not for the purpose of changing or influencing control. While a large institutional stake can be seen as a positive signal of confidence, this filing alone does not provide new fundamental information about Beam Therapeutics' operational performance or strategic direction to warrant a change from a 'hold' position. It primarily confirms a significant, stable institutional presence.
Keywords
Beam Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.